Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04922554
Recruitment Status : Recruiting
First Posted : June 10, 2021
Last Update Posted : April 19, 2022
Information provided by (Responsible Party):
Paratek Pharmaceuticals Inc

Brief Summary:
The purpose of this study is to evaluate the efficacy, safety and tolerability of oral omadacycline as compared to placebo in the treatment of adults with Nontuberculous Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc)

Condition or disease Intervention/treatment Phase
Mycobacterium Infections, Nontuberculous Mycobacterium Abscessus Infection Nontuberculous Mycobacterial Lung Disease Nontuberculous Mycobacterial Pulmonary Infection Drug: Omadacycline Oral Tablet Drug: Placebo Phase 2

Detailed Description:
The total duration of subject participation in the study is approximately 5 months which includes a total duration of study treatment for approximately 3 months (84 days). Eligible participants will be randomized 1.5:1 to receive 3 months of treatment with either omadacycline or placebo (monotherapy). The study will use a double-dummy design in order to maintain the study blinding.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex
Actual Study Start Date : October 15, 2021
Estimated Primary Completion Date : September 2023
Estimated Study Completion Date : October 2023

Arm Intervention/treatment
Experimental: Omadacycline 300 mg PO
omadacycline 150 mg tablets (x 2) administered orally, once daily, q24h
Drug: Omadacycline Oral Tablet
omadacycline 300 mg orally, once daily (150 mg tablets x 2)
Other Name: Nuzyra

Placebo Comparator: Placebo PO
Placebo tablets resembling omadacycline (x 2) administered once daily, q24h
Drug: Placebo
placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
Other Name: placebo tablets

Primary Outcome Measures :
  1. Clinical Response on NTM Symptom Assessment Scale at Day 84 [ Time Frame: Day 1 to Day 84/EOT ]
    Improvement in severity of at least 50% of symptoms present at baseline

  2. Reported adverse events (AEs) [ Time Frame: Day 1 to Day 84/EOT ]
    To assess reported adverse events

  3. Changes from baseline in laboratory tests [ Time Frame: Day 1 to Day 84/EOT ]
    To assess the incidents of abnormal hematology, biochemistry, coagulation and urinalysis assessments following 84 days of IP administration

  4. Clinically significant (CS), outside normal range laboratory tests [ Time Frame: Day 1 to Day 84/EOT ]
    To assess the incidents of CS abnormal hematology, biochemistry, coagulation and urinalysis assessments following 84 days of IP administration

  5. Changes from baseline in vital signs [ Time Frame: Day 1 to Day 84/EOT ]
    To assess the incidents of abnormal heart rate and blood pressure assessments following 84 days of IP administration

  6. Clinically significant (CS) vital signs [ Time Frame: Day 1 to Day 84/EOT ]
    To assess the incidents of CS heart rate and blood pressure following 84 days of IP administration

  7. Changes from baseline in electrocardiogram (ECG) [ Time Frame: Day 1 to Day 84/EOT ]
    To assess the incidents of abnormal heart rate, cardiac rhythm, PR interval, RR interval, QRS interval, QT interval and QTc interval assessments following 84 days of IP administration

  8. Clinically significant (CS) electrocardiogram (ECG) findings [ Time Frame: Day 1 to Day 84/EOT ]
    To assess the incidents of CS and QTc interval assessments following 84 days of IP administration

Secondary Outcome Measures :
  1. Change from baseline in the total score of the Quality of Life - Bronchiectasis (QOL-B) questionnaire [ Time Frame: Day 1 to Day 84/EOT ]
  2. Change from baseline in global score and individual domain scores of the St. George Respiratory Questionnaire (SGRQ) [ Time Frame: Day 1 to Day 84/EOT ]
  3. Change from baseline in Patient-Reported Outcomes Measurement Information System Short Form v1.0 - Fatigue 7a Daily (PROMIS-7a) [ Time Frame: Day 1 to Day 84/EOT ]
  4. Change from baseline in Patient Clinical Impression of Severity (PGI-S) [ Time Frame: Day 1 to Day 84/EOT ]
  5. Change from baseline in Patient Clinical Impression of Change (PGI-C) [ Time Frame: Day 1 to Day 84/EOT ]
  6. Change from baseline in Clinical Global Impression - Severity of Illness (CGI-S) [ Time Frame: Day 1 to Day 84/EOT ]
  7. Change from baseline in Clinical Global Impression - Improvement (CGI-I) [ Time Frame: Day 1 to Day 84/EOT ]
  8. Patients reporting no new symptoms with a severity worse than mild on the NTM Symptom Assessment Questionnaire [ Time Frame: Day 1 to Day 84/EOT ]
  9. Decrease in quantitative sputum culture at Day 84 [ Time Frame: Day 1 to Day 84/EOT ]
  10. Time to growth in liquid medium only [ Time Frame: Day 1 to Day 84/EOT ]
  11. Time to first negative sputum culture [ Time Frame: Day 1 to Day 84/EOT ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Has a diagnosis of Nontuberculous Mycobacterial pulmonary disease caused by MABc
  • Has at least 2 of the following NTM-infection symptoms present at Screening and Baseline: chronic cough, coughing up blood (hemoptysis), wheezing, chest pain, frequent throat clearing, phlegm or sputum production, shortness of breath, fatigue, fever, night sweats, poor appetite, and/or weight loss.
  • At least 1 positive pulmonary (sputum) culture for MABc in the 6 months prior to Screening and 1 positive culture at Screening
  • Radiographic evidence of MABc infection via computed tomography (CT) scan of the chest within 3 months prior to Screening
  • In the opinion of the investigator, guideline-directed antibiotic therapy for treatment of MABc will not be required within the next 3 months, and a delay, in order for the subject to participate in a placebo-controlled clinical trial, is considered reasonable and clinically acceptable
  • Additional inclusion criteria as per protocol

Key Exclusion Criteria:

  • Has received antibiotic treatment within 6 months prior to Screening for MABc or MAC
  • Has received systemic or inhaled antibiotic therapy (other than chronic macrolide therapy) within 4 weeks prior to Screening
  • Has any of the following medical conditions:
  • Active pulmonary malignancy, or any type of malignancy requiring chemotherapy or radiation within 1 year prior to Screening
  • Active allergic bronchopulmonary mycosis, or any other condition requiring chronic treatment with systemic corticosteroids within 90 days prior to Screening
  • Radiologic evidence of cavitary disease
  • Known active pulmonary tuberculosis
  • Cystic fibrosis
  • History of lung transplantation
  • Another advanced lung disease with a known percent predicted forced expiratory volume in 1 second < 30%.
  • Disseminated or extra-pulmonary NTM disease
  • Has been previously treated with omadacycline
  • Has a history of hypersensitivity or allergic reaction to tetracyclines
  • Additional exclusion criteria as per protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04922554

Layout table for location contacts
Contact: Alissa Sirbu 617.459.5307
Contact: Amy Manley 484.682.4976

Layout table for location information
United States, Alabama
University of Alabama Cystic Fibrosis Research Center Recruiting
Birmingham, Alabama, United States, 35294
Contact: Bryan Garcia, MD   
Principal Investigator: Bryan Garcia, MD         
United States, California
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Hanna Gratny    650-725-8083   
Principal Investigator: Stephen Ruoss, MD         
United States, District of Columbia
Georgetown University Hospital Recruiting
Washington, District of Columbia, United States, 20057
Contact: Amen Hamed    202-444-0895   
Principal Investigator: Anne O'Donnell, MD         
United States, Florida
Central Florida Pulmonary Group Recruiting
Altamonte Springs, Florida, United States, 32701
Contact: Kathleen Summo    407-841-1100 ext 225   
Principal Investigator: Tabarak Qureshi, MD         
St. Francis Medical Institute Recruiting
Clearwater, Florida, United States, 33765
Contact: Francis J Averill, MD    727-210-4606   
Principal Investigator: Francis J Averill, MD         
University of South Florida Recruiting
Tampa, Florida, United States, 33612
Contact: Beth Montera    813-844-7948   
Principal Investigator: Chakrapol Sriaroon, MD         
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287
Contact: NTMBresearch    410-550-4968   
Principal Investigator: Christopher Lippincott, MD         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Colleen Richmond    314-454-0058   
Principal Investigator: Andrej Spec, MD         
United States, New Hampshire
Dartmouth-Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Aboubacar Cherif    603-650-2392   
Principal Investigator: Elizabeth Talbot, MD         
United States, New York
Pulmonary Health Physicians, PC Recruiting
Liverpool, New York, United States, 13088
Contact: Jeannine Moore    315-234-0823   
Principal Investigator: Sherif El Bayadi, MD         
United States, North Carolina
Southeastern Research Center Recruiting
Winston-Salem, North Carolina, United States, 27103
Contact: Karen Mccutcheon    336-659-8414   
Principal Investigator: Reginald Fowler, MD         
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Ted Warnock, BS    503-494-8121   
Principal Investigator: Kevin Winthrop, MPH, MD         
United States, South Carolina
Medical University of South Carolina (MUSC) Recruiting
Charleston, South Carolina, United States, 29425
Contact: Angela Millare    843-792-3710   
Principal Investigator: Patrick Flume, MD         
United States, Texas
Baylor University Medical Center / Baylor Scott and White Research Institute Not yet recruiting
Dallas, Texas, United States, 75201
Contact: Joost Felius    214-818-8943   
Principal Investigator: Randall Rosenblatt, MD         
The University of Texas Health Science Center at Tyler Recruiting
Tyler, Texas, United States, 75708
Contact: Rebekah Hibbard, BS, CCRC    903-877-8246   
Principal Investigator: Julie Philley, MD         
United States, Wisconsin
University of Wisconsin Hospitals and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Jordan Bialock    608-263-4818   
Principal Investigator: Elizabeth Ann Misch, MD         
Sponsors and Collaborators
Paratek Pharmaceuticals Inc
Layout table for investigator information
Study Chair: Gail Berman, MD Paratek Pharmaceuticals Inc
Layout table for additonal information
Responsible Party: Paratek Pharmaceuticals Inc Identifier: NCT04922554    
Other Study ID Numbers: PTK0796-NTM-20203
First Posted: June 10, 2021    Key Record Dates
Last Update Posted: April 19, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Paratek Pharmaceuticals Inc:
Nontuberculous Mycobacteria (NTM)
Mycobacterium abscessus complex (MABc)
NTM pulmonary disease
NTM lung disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Mycobacterium Infections
Mycobacterium Infections, Nontuberculous
Lung Diseases
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses